EU Approves Zokovea for COVID-19 Post-Exposure Prophylaxis

The European Commission has granted marketing authorization for Zokovea (ensitrelvir), making it the first oral antiviral medicine approved in the European Union for post-exposure prophylaxis (PEP) of COVID-19. This approval, based on results from the Phase 3 SCORPIO-PEP study, allows adults and adolescents aged 12 and older to use the drug following household exposure to the virus. This marks a new option for preventing COVID-19 after exposure.